8-cyclopentyl-3-(3-((4-(fluorosulfonyl)benzoyl)oxy)propyl)-1-propylxanthine has been researched along with adenosine in 9 studies
| Studies (8-cyclopentyl-3-(3-((4-(fluorosulfonyl)benzoyl)oxy)propyl)-1-propylxanthine) | Trials (8-cyclopentyl-3-(3-((4-(fluorosulfonyl)benzoyl)oxy)propyl)-1-propylxanthine) | Recent Studies (post-2010) (8-cyclopentyl-3-(3-((4-(fluorosulfonyl)benzoyl)oxy)propyl)-1-propylxanthine) | Studies (adenosine) | Trials (adenosine) | Recent Studies (post-2010) (adenosine) |
|---|---|---|---|---|---|
| 28 | 0 | 12 | 32,536 | 1,075 | 8,930 |
| Protein | Taxonomy | 8-cyclopentyl-3-(3-((4-(fluorosulfonyl)benzoyl)oxy)propyl)-1-propylxanthine (IC50) | adenosine (IC50) |
|---|---|---|---|
| high affinity choline transporter 1 isoform a | Homo sapiens (human) | 0.3851 | |
| Sodium/nucleoside cotransporter 1 | Homo sapiens (human) | 5.5 | |
| Sodium/nucleoside cotransporter 2 | Homo sapiens (human) | 5.5 | |
| Adenosine receptor A3 | Homo sapiens (human) | 0.0011 | |
| Adenosine receptor A1 | Homo sapiens (human) | 0.0023 | |
| Equilibrative nucleoside transporter 1 | Homo sapiens (human) | 63 | |
| Solute carrier family 28 member 3 | Homo sapiens (human) | 3.3 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (33.33) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 3 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
| Baker, SP; Belardinelli, L; Ruble, J; Scammells, PJ; Shryock, JC; Srinivas, M | 1 |
| Baker, SP; Belardinelli, L; Dennis, DM; Shryock, JC; Srinivas, M | 1 |
| Belardinelli, L; Dennis, DM; Morey, TE | 1 |
| Baker, SP; Belardinelli, L; Scammells, PJ | 1 |
| Alhaj, M; Bozarov, A; Christofi, FL; Cooke, HJ; Grants, I; Hassanain, HH; Ren, T; Wang, YZ; Wunderlich, J; Yu, JG | 1 |
| Gesztelyi, R; Haines, DD; Juhasz, B; Kiss, Z; Pak, K; Szentmiklosi, AJ; Tosaki, A; Varga, B; Zsuga, J | 1 |
| Erdei, T; Gesztelyi, R; Juhasz, B; Lampe, N; Papp, C; Pinter, A; Szabó, K; Szentmiklosi, AJ; Szilvássy, Z; Zsuga, J | 1 |
| Erdei, T; Gesztelyi, R; Juhasz, B; Kiss, R; Papp, C; Pinter, A; Szabo, AM; Szilvassy, Z; Viczjan, G; Zsuga, J | 1 |
9 other study(ies) available for 8-cyclopentyl-3-(3-((4-(fluorosulfonyl)benzoyl)oxy)propyl)-1-propylxanthine and adenosine
| Article | Year |
|---|---|
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
A novel irreversible antagonist of the A1-adenosine receptor.
Topics: Adenosine; Animals; Carbachol; Dose-Response Relationship, Drug; GTP-Binding Proteins; Guanosine 5'-O-(3-Thiotriphosphate); Guanylyl Imidodiphosphate; Guinea Pigs; Heart; Heart Atria; In Vitro Techniques; Isoproterenol; Kinetics; Membrane Potentials; Myocardium; Patch-Clamp Techniques; Potassium Channels; Purinergic P1 Receptor Antagonists; Radioligand Assay; Receptors, Purinergic P1; Theophylline; Xanthines | 1996 |
Differential A1 adenosine receptor reserve for two actions of adenosine on guinea pig atrial myocytes.
Topics: Adenosine; Animals; Dose-Response Relationship, Drug; Guinea Pigs; Heart Atria; Potassium Channels; Purinergic P1 Receptor Agonists; Receptors, Purinergic P1; Xanthines | 1997 |
Validation of Furchgott's method to determine agonist-dependent A1-adenosine receptor reserve in guinea-pig atrium.
Topics: Adenosine; Animals; Blood Pressure; Dose-Response Relationship, Drug; Female; Guinea Pigs; Heart Atria; In Vitro Techniques; Male; Methods; Purinergic P1 Receptor Agonists; Radioligand Assay; Receptors, Purinergic P1; Xanthines | 1998 |
Differential A(1)-adenosine receptor reserve for inhibition of cyclic AMP accumulation and G-protein activation in DDT(1) MF-2 cells.
Topics: Adenosine; Cells, Cultured; Cyclic AMP; Dose-Response Relationship, Drug; GTP-Binding Proteins; Guanosine 5'-O-(3-Thiotriphosphate); Muscle, Smooth; Receptors, Purinergic P1; Xanthines | 2000 |
Activation of adenosine low-affinity A3 receptors inhibits the enteric short interplexus neural circuit triggered by histamine.
Topics: Adenosine; Animals; Chlorides; Cimetidine; Colon; Dihydropyridines; Dimaprit; Dose-Response Relationship, Drug; Enteric Nervous System; Gastrointestinal Motility; Guinea Pigs; Histamine; Histamine Agonists; Histamine H2 Antagonists; In Vitro Techniques; Intestinal Secretions; Male; Mecamylamine; Muscle Contraction; Muscle Relaxation; Muscle, Smooth; Neural Inhibition; Neurogenic Bowel; Neurokinin-1 Receptor Antagonists; Nicotinic Antagonists; Piperidines; Propane; Receptor, Adenosine A1; Receptor, Adenosine A3; Receptors, Histamine H2; Receptors, Neurokinin-1; Reflex; Theophylline; Xanthines | 2009 |
The guinea pig atrial A1 adenosine receptor reserve for the direct negative inotropic effect of adenosine.
Topics: Adenosine; Adenosine A1 Receptor Antagonists; Animals; Atrial Function; Dose-Response Relationship, Drug; Guinea Pigs; Heart Atria; In Vitro Techniques; Male; Myocardial Contraction; Receptor, Adenosine A1; Thioinosine; Xanthines | 2013 |
Methodical Challenges and a Possible Resolution in the Assessment of Receptor Reserve for Adenosine, an Agonist with Short Half-Life.
Topics: Adenosine; Animals; Biological Transport; Computer Simulation; Equilibrative Nucleoside Transporter 1; Guinea Pigs; Half-Life; Kinetics; Models, Statistical; Myocardium; Myocytes, Cardiac; Purinergic P1 Receptor Antagonists; Receptor, Adenosine A1; Thioinosine; Xanthines | 2017 |
An Advanced In Silico Modelling of the Interaction between FSCPX, an Irreversible A
Topics: Adenosine; Adenosine A1 Receptor Antagonists; Animals; Dose-Response Relationship, Drug; Guinea Pigs; Nucleobase Transport Proteins; Receptor, Adenosine A1; Xanthines | 2019 |